Pancreatic Cancer Research

ResearcherUniversity Medical Center Hamburg-EppendorfActive in the last 2 years

Udo Schumacher

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1494-5956; OpenAlex author ID A5062826138. Sources: OpenAlex.

Their work

Papers
9 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
28
Papers, trials and grants by year

2013: 1 paper · 2014: 3 papers · 2015: none · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper

Papers 9

  1. Epithelial and Mesenchymal-like Pancreatic Cancer Cells Exhibit Different Stem Cell Phenotypes Associated with Different Metastatic Propensities. Co-author DOI 10.3390/cancers16040686↗
  2. Integrin alpha-V is an important driver in pancreatic adenocarcinoma progression. Co-author DOI 10.1186/s13046-021-01946-2↗
  3. Biperiden and mepazine effectively inhibit MALT1 activity and tumor growth in pancreatic cancer. Co-author DOI 10.1002/ijc.32567↗
  4. Liver metastasis of pancreatic cancer: the hepatic microenvironment impacts differentiation and self-renewal capacity of pancreatic ductal epithelial cells. Co-author DOI 10.18632/oncotarget.25884↗
  5. Is hyaluronan deposition in the stroma of pancreatic ductal adenocarcinoma of prognostic significance? Last author DOI 10.1371/journal.pone.0178703↗
  6. L1CAM promotes enrichment of immunosuppressive T cells in human pancreatic cancer correlating with malignant progression. Co-author DOI 10.1016/j.molonc.2014.03.001↗
  7. Carcinoembryonic antigen-related cell adhesion molecules (CEACAM) 1, 5 and 6 as biomarkers in pancreatic cancer. Last author DOI 10.1371/journal.pone.0113023↗
  8. Serum EpCAM expression in pancreatic cancer. Co-author PMID 25202052↗
  9. Selectin binding is essential for peritoneal carcinomatosis in a xenograft model of human pancreatic adenocarcinoma in pfp--/rag2-- mice. Last author DOI 10.1136/gutjnl-2011-300629↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Florian Gebauer · 5 shared papers, 2013–2021 · strength 0.32
  2. Jakob Robert Izbicki · 5 shared papers, 2013–2021 · strength 0.31
  3. Susanne Sebens · 3 shared papers, 2014–2024 · strength 0.28
  4. Daniel Wicklein · 5 shared papers, 2013–2021 · strength 0.26
  5. Hendrike Knaack · 2 shared papers, 2018–2024 · strength 0.25
  6. Lisa-Marie Philipp · 2 shared papers, 2018–2024 · strength 0.25
  7. Jan-Paul Gundlach · 2 shared papers, 2018–2024 · strength 0.25
  8. Marius Kemper · 2 shared papers, 2017–2021 · strength 0.20
  9. Michael Tachezy · 3 shared papers, 2014–2021 · strength 0.20
  10. Maximilian Bockhorn · 4 shared papers, 2013–2020 · strength 0.20
  11. Anne‐Sophie Mehdorn · 1 shared paper, 2024 · strength 0.18
  12. Achim Michael Aigner · 1 shared paper, 2021 · strength 0.11
  13. Alexander T. El Gammal · 1 shared paper, 2020 · strength 0.08
  14. Leonie Konczalla · 1 shared paper, 2020 · strength 0.08
  15. Gerrit Wolters‐Eisfeld · 1 shared paper, 2020 · strength 0.08
  16. Bianca T. Hofmann · 1 shared paper, 2020 · strength 0.08
  17. Cenap Güngör · 1 shared paper, 2020 · strength 0.08
  18. Faik Güntac Uzunoglu · 1 shared paper, 2020 · strength 0.08
  19. Sascha Rahn · 1 shared paper, 2018 · strength 0.07
  20. Lennart Lenk · 1 shared paper, 2018 · strength 0.07
  21. Lauritz Miarka · 1 shared paper, 2018 · strength 0.07
  22. Yogesh Kumar Vashist · 1 shared paper, 2014 · strength 0.04
  23. Daniela Wesch · 1 shared paper, 2014 · strength 0.04
  24. H. Schäfer · 1 shared paper, 2014 · strength 0.04
  25. Christoph Röcken · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.